secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jaguar Health, Inc. (JAGX)
CIK:        0001585608
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001104659-23-091022
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jaguar Health Q2 net loss $12.2M, revenue $2.7M (+36% QoQ); OnTarget Phase 3 topline due late Oct
--------------------------------------------------------------------------------

- Net loss attributable to shareholders $12.2M in Q2 2023 vs $9.4M in Q2 2022; diluted EPS ($0.42) vs ($0.12).
- Combined net revenue for Mytesi and Canalevia-CA1 $2.7M, up 36% QoQ but down 8% YoY.
- Loss from operations increased to $8.1M from $6.5M YoY; R&D spend rose to $4.3M from $2.5M.
- Mytesi prescription volume up 4% sequentially; Canalevia-CA1 net revenue $39K (+40% QoQ).
- Top line results from Phase 3 OnTarget trial of crofelemer for cancer therapy-related diarrhea expected late October 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1585608/000110465923091022/0001104659-23-091022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1585608/000110465923091022/tm2323630d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-091022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer